INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAPRNewsWire • Thursday
Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep CorrectionSeeking Alpha • Monday
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline ProgressZacks Investment Research • 11/06/26
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/05/26
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate UpdatesGlobeNewsWire • 11/05/26
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer TranscriptSeeking Alpha • 10/29/26
Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA FilingMarketBeat • 10/29/26
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer TwistInvestors Business Daily • 10/29/26
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/29/26
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)GlobeNewsWire • 10/29/26
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine StrategyGlobeNewsWire • 10/28/26
Why Investors Need to Take Advantage of These 2 Medical Stocks NowZacks Investment Research • 10/27/26
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026GlobeNewsWire • 10/27/26
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026GlobeNewsWire • 10/26/26
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced MelanomaGlobeNewsWire • 10/23/26
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 10/19/26